Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$171M |
Are Inhibrx Biosciences Insiders Buying or Selling?
Inhibrx Biosciences (INBX) has had 16 insider transactions in the past 90 days, including 14 buys and 2 sells. The most recent was Mark Lappe, who bought 3,000 shares at $101.70 on September 28, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the INBX AI Score. For government officials trading this stock, see INBX congressional trading.
Who’s Trading Inhibrx Biosciences Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | Sold $11M | 3 | Oct 7, 2025 |
| Mark Lappe | Bought $3.6M | 10 | Sep 28, 2026 |
| Kayyem Jon Faiz | Bought $2.3M | 5 | Sep 23, 2026 |
| DOUGLAS FORSYTH | Bought $290,000 | 1 | Sep 8, 2026 |
| KIMBERLY MANHARD | Sold $110,000 | 2 | Sep 15, 2026 |
Recent Inhibrx Biosciences Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mark Lappe | Sep 28, 2026 | Buy | 3,000 | $101.7 | $310,000 |
| Mark Lappe | Sep 28, 2026 | Buy | 1,500 | $98.88 | $150,000 |
| Mark Lappe | Sep 25, 2026 | Buy | 3,324 | $98.87 | $330,000 |
| Mark Lappe | Sep 25, 2026 | Buy | 2,176 | $99.6 | $220,000 |
| Kayyem Jon Faiz | Sep 23, 2026 | Buy | 5,000 | $100 | $500,000 |
| Kayyem Jon Faiz | Sep 16, 2026 | Buy | 5,000 | $100 | $500,000 |
| KIMBERLY MANHARD | Sep 15, 2026 | Sell | 500 | $105.05 | $53,000 |
| KIMBERLY MANHARD | Sep 9, 2026 | Sell | 500 | $115.8 | $58,000 |
| Kayyem Jon Faiz | Sep 8, 2026 | Buy | 5,000 | $113.52 | $570,000 |
| Mark Lappe | Sep 8, 2026 | Buy | 9,681 | $112.28 | $1.1M |
| Mark Lappe | Sep 8, 2026 | Buy | 6,605 | $100.64 | $660,000 |
| Mark Lappe | Sep 8, 2026 | Buy | 5,895 | $99.29 | $590,000 |
| Mark Lappe | Sep 8, 2026 | Buy | 1,219 | $111.88 | $140,000 |
| Mark Lappe | Sep 8, 2026 | Buy | 1,100 | $107.12 | $120,000 |
| DOUGLAS FORSYTH | Sep 8, 2026 | Buy | 2,500 | $114.65 | $290,000 |
| Mark Lappe | Sep 8, 2026 | Buy | 500 | $108.24 | $54,000 |
| VIKING GLOBAL INVESTORS LP | Oct 7, 2025 | Sell | 308,643 | $32.25 | $10M |
| VIKING GLOBAL INVESTORS LP | Oct 7, 2025 | Sell | 25,042 | $32.25 | $810,000 |
| VIKING GLOBAL INVESTORS LP | Oct 7, 2025 | Sell | 16,315 | $32.25 | $530,000 |
| Kayyem Jon Faiz | Nov 20, 2024 | Buy | 18,750 | $14.19 | $270,000 |
| Kayyem Jon Faiz | Nov 19, 2024 | Buy | 34,843 | $14.23 | $500,000 |
Frequently Asked Questions: Inhibrx Biosciences Insider Trading
In the past 90 days, Inhibrx Biosciences insiders have made 14 buys and 2 sells. The net buying may indicate insider confidence in the company’s outlook.
The most recent sale was by KIMBERLY MANHARD who sold 500 shares on September 15, 2026. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Lappe Mark has bought the most INBX stock in the last 2 years, with a total value of $3.6M.
VIKING GLOBAL INVESTORS LP has sold the most INBX stock in the last 2 years, with a total value of $11M.
The total value of insider transactions for Inhibrx Biosciences in the last 2 years is negative, amounting to -$5.1M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
